F-star Therapeutics, Inc.
F-star Therapeutics, Inc. (FSTX) Revenue
Annual & quarterly revenue history · segment & region breakdown
FSTX · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsF-star Therapeutics, Inc. trailing twelve-month (TTM) revenue is $0.02B, an increase of 88.05% year-over-year from $0.02B in FY2021.
Revenue trend
2021 – 2016 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2021-12-31 | $0.02B | +$0.01B | +88.05% |
| 2020-12-31 | $0.01B | -$0.02B | -60.26% |
| 2019-12-31 | $0.03B | +$0.03B | — |
| 2018-12-31 | $0.00B | +$0.00B | — |
| 2017-12-31 | $0.00B | +$0.00B | — |
| 2016-12-31 | $0.00B | — | — |
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income F-star Therapeutics, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
F-star Therapeutics, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from F-star Therapeutics, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
FSTX revenue · 4 questionsFSTX's trailing twelve-month (TTM) revenue is $0.02B. That is an increase of 88.05% year-over-year from $0.02B in FY2021.
▸ Source: FMP · F-star Therapeutics, Inc. SEC filings · GAAP · F-star Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026